Časopisy (871)
EDITORIAL ........................................................................................................... 62
PŮVODNÍ PRÁCE
J. Libiger, J. Švestka a český tým hodnotitelù studie:
Olanzapin verzus haloperidol: Výsledky akutní fáze dvojitì slepé
studie úèinnosti nového atypického neuroleptika u pacientù se
schizofrenní a schizoafektivní psychózou.............................................................. 64
J. Židovská, Š. Růžičková, M. Vojtíšková, E. Havrdová, J. Roth, J. Kapras:
DNA analýza genu Huntingtonovy choroby v české populaci .................................. 70
J. Bečka, E. Nagyová, J. Horáček:
Charakteristiky snù u vybraných duševních onemocnění .......................................... 74
PŘEHLEDNÉ ČLÁNKY
C. Höschl: Teorie deprese ................................................................................... 78
M. Alda: Co nového v genetickém výzkumu maniodepresivity? ................................ 86
P. Mohr: Deficitní syndrom ve schizofrenii: pøehled ................................................ 94
R. Rokyta: Bolest a její patofyziologie ................................................................ 103
J. Patočka, M. Tichý, D. Řípová, R. Jirák: Apolipoprotein E
jako rizikový faktor demence .............................................................................. 108
KAZUISTIKY
L. Motlová: Olanzapin v léèbì schizofrenie ........................................................... 112
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová antipsychotika II. generace: Olanzapin ....................................................... 115
ZPRÁVY ......................................................................................................... 124
Přečetli jsme za Vás ....................................................................................... 138
DOPISY, DISKUZE A OHLASY.......................................................................... 143
NOVÉ KNIHY.................................................................................................... 147
INFORMACE ................................................................................................... 149
EDITORIAL ....................................................................................................... 62
ORIGINAL PAPERS
J. Libiger, J. Švestka and the Czech team of study evaluators:
Olanzapine Versus Haloperidol: Acute Phase Results
of the Double Blind Randomized Clinical Study of Efficacy
of a New Atypical Antipsychotic in Patients with
Schizophrenia and Schizoaffective Psychosis ...................................................... 64
J. Židovská, Š. Růžičková, M. Vojtíšková, E. Havrdová, J. Roth, J. Kapras:
DNA analysis of the Huntington's Disease Gene
in the Czech Population ..................................................................................... 70
J. Bečka, E. Nagyová, J. Horáček:
Dream Characteristics in Selected Mental Disorders ............................................ 74
REVIEWS
C. Höschl: Theory of Depression ........................................................................ 78
M. Alda: What is New in Genetic Research of Bipolar Illness ................................ 86
P. Mohr: Deficit Syndrome of Schizophrenia: A Review ........................................ 94
R. Rokyta: Pain and its Pathophysiology ......................................................... 103
J. Patočka, M. Tichý, D. Řípová, R. Jirák: Apolipoprotein E
as a Risk Factor of Dementia ........................................................................... 108
CASE REPORTS
L. Motlová: Olanzapine in the Treatment of Schizophrenia .................................... 112
NEW PSYCHOTROPICS
J. Švestka:
New Antipsychotics of the 2nd generation: Olanzapine ....................................... 115
COMMUNICATIONS ........................................................................................ 124
We have read for you ....................................................................................... 138
CORRESPONDENCE, DISCUSSION................................................................. 143
NEW BOOKS ................................................................................................. 147
INFORMATION ............................................................................................... 149
EDITORIAL ......................................................................................................................... 2
PŘEHLEDNÉ ČLÁNKY
P. Petrovický:
Struktury a dráhy monoaminových systémů (noradrenalin, dopamin, serotonin) ........................ 4
K. Šonka:
Obstrukční spánkový apnoický syndrom ............................................................................. 12
S. Liptáková, L. Velíšek:
Katastrofické epilepsie dìtského vìku a jejich modely ........................................................... 18
R. Balon:
Výuka psychiatrie ve Spojených státech ............................................................................ 23
Z. Dytrych:
Nové sociální fenomény a duševní zdraví v ČR ................................................................... 28
KRÁTKÁ SDĚLENÍ........................................................................................................... 31
NOVÁ PSYCHOFARMAKA
J. Švestka:
Nová antidepresiva: Tianeptin, klinicko-farmakologický paradox ........................................... 32
ZPRÁVY ........................................................................................................................ 38
DOPISY, DISKUSE A OHLASY......................................................................................... 51
NOVÉ KNIHY ................................................................................................................. 53
INFORMACE.................................................................................................................. 59
Rejstříky
EDITORIAL ..................................................................................................................... 2
REVIEWS
P. Petrovický:
Structures and Pathways of Monoamine Systems (Noradrenaline, Dopamine, Serotonine) ..... 4
K. Šonka:
Obstructive Sleep Apnea Syndrome ................................................................................. 12
S. Liptáková, L. Velíšek:
Catastrophic Epilepsies of Childhood and their Models ...................................................... 18
R. Balon:
Teaching of Psychiatry in the United States ..................................................................... 23
Z. Dytrych:
New Social Phenomena and Mental Health in Czech Republic ........................................... 28
BRIEF ARTICLES .......................................................................................................... 31
NEW PSYCHOTROPICS
J. Švestka:
New Antidepressants: Tianeptine, the Clinical-Pharmacological Paradox ............................. 32
COMMUNICATIONS ...................................................................................................... 38
CORRESPONDENCE, DISCUSSION ............................................................................. 51
NEW BOOKS ............................................................................................................. 53
INFORMATION ........................................................................................................... 59
Index
EDITORIAL ........................................................................................................... 1
SCIENTIFIC PROGRAMME .............................................................................. 7
SUNDAY, NOVEMBER 13
Plenary Session
Asthma in Childhood – New Understanding .................................................. 15
Neonatal Lung Disease
(coord.: Sailesh Kotecha, UK) ......................................................................... 16
Management of Anaphylaxis
(coord.: Antonella Muraro, I) .......................................................................... 17
Smoking – Respiratory and Allergic Consequences
(coord.: Elif Dagli, TR) ..................................................................................... 19
Early Allergy Diagnosis Event
(coord.: Philippe Eigenmann, CH) .................................................................. 20
Tools in the Allergy Diagnosis
(coord.: Bodo Niggemann, D) ......................................................................... 22
Imaging the Lung Beyond the Chest X-ray
(coord.: Catherine Owens, UK) ...................................................................... 26
MONDAY, NOVEMBER 14
Plennary Session
Prevention of Allergic Disease .......................................................................... 27
Immunotherapy in Children
(coord.: Erkka Valovirta, SF) ........................................................................... 28
Primary Ciliary Dyskinesia
(coord.: Andrew Bush, UK) .............................................................................. 30
The Allergic Child at School
(coord.: Magnus Borres) ................................................................................... 31
Asthma Guidelines
(coord.: Petr Pohunek, CZ) .............................................................................. 32
Paediatric Tuberculosis – What Is New?
(coord.: Elif Dagli, TR) ..................................................................................... 35
Non-IgE Mediated Allergy
(coord.: Kirsten Beyer, D) ................................................................................ 36
TUESDAY, NOVEMBER 15
Plenary Session
Paediatric Respiratory Year in Review ............................................................. 38
Food Allergy
(coord.: Philippe Eigenmann, CH) ................................................................. 40
Atopic Eczema: Various Features and Relations to New Therapies
(coord.: Fabienne Rance, F) ............................................................................ 41
Interstitial Lung Disease in Children
(coord.: Robert Dinwiddie, UK) ..................................................................... 42
Special Features in the Adolescents
(coord.: Kai-Håkon Carlsen, N) ....................................................................... 44
Lower Respiratory Tract Infection
(coord.: Petr Pohunek, CZ) ............................................................................. 45
From Sensitization to Aeroallergenes to Food Allergy
(coord.: Cristina Pascual, E) ............................................................................. 47
Incoming oral presentations ............................................................................. 48
Incoming poster presentations ......................................................................... 50
PŘEDNÁŠKY
J. Švihovec
Léková politika .......................................................................................................... 11
N. Khaltaev
Program WHO proti astmatu a alergii: GARD ........................................................ 15
V. Kašák, V. Špičák
Test kontroly astmatu ................................................................................................. 19
J. Chlumský
Význam monitorování zánìtu u pacientù s bronchiálním astmatem .................................... 23
T. Sýkora
Výskyt alergických onemocnění a jejich příznakù u žákù osmých tříd
a studentù tercií víceletých gymnázií v okrese Pardubice .................................. 27
J. Bystroň, L. Heller, L. Pavelková, J. Braunová, D. Pazderová,
H. Ostrèilová, R. Dokoupilová, T. Utíkalová, J. Tillich, J. Peprníková
Jak se žije astmatikùm na Moravì? ........................................................................... 30
E. Seberová
Jak se žije polinotikùm ............................................................................................... 35
V. Petrù
Anafylaktické reakce .................................................................................................. 41
INFORMACE ......................................................................................................... 47
CONTENTS
EDITORIAL ........................................................................................................... 1
WORLD ASTMA DAY 2005 ................................................................................. 6
LECTURES
J. Švihovec
Drug policy ................................................................................................................. 11
N. Khaltaev
WHO programme against Asthma and Allergy: GARD ......................................... 15
V. Kašák, V. Špičák
Asthma control test .................................................................................................... 19
J. Chlumský
How do the asthmatic patients in Moravia Live? .................................................... 23
T. Sýkora
Alergic illness and their symptomps occurance among pupils
of the eights forms and students of the third forms
of grammar schools in Pardubice district ............................................................. 27
J. Bystroň, L. Heller, L. Pavelková, J. Braunová,
D. Pazderová, H. Ostrčilová, R. Dokoupilová,
T. Utíkalová, J. Tillich, J. Peprníková
How do the asthmatic patients in Moravia Live? .................................................... 30
E. Seberová
What is the life of patients with pollen allergy ......................................................... 35
V. Petrù
Anaphylactic reactions ............................................................................................... 41
INFORMATION ..................................................................................................... 47
EDITORIAL .......................................................................................................... 1 ÚVOD .................................................................................................................. 7
J. Blahoš
Aktivní společnost alergologie a klinické imunologie ČLS JEP ................................... 7
C. John
Klinická imunologie stále živá ................................................................................. 7
P. Barták
Jak běží čas ......................................................................................................... 9
1. ČÁST
ČSAKI – Česká společnost alergologie a klinické imunologie ................................... 13
ALERGOLOGIE A KLINICKÁ IMUNOLOGIE
Na Slupi a na Karlově náměstí .............................................................................. 22
Fakultní nemocnice Královské Vinohrady a 3. LF UK v Praze ................................... 23
Pediatrická alergologie: Sokolská – Motol – Bulovka ................................................ 26
Brno ................................................................................................................... 28
Olomouc ............................................................................................................. 31
Hradec Králové ..................................................................................................... 35
Ostravsko ............................................................................................................ 37
Plzeň .................................................................................................................. 39
České Budìjovice ................................................................................................. 40
Ústí nad Labem ................................................................................................... 41
50 let české alergologie – Ohlédnutí s úsměvem ..................................................... 49
2. ČÁST
V. Špičák
Správná alergologická praxe v medicínì založené na dùkazech ................................ 52
Revize názvosloví v alergologii ............................................................................... 55
Standard testování kožními Prick testy a senzibilizace
ke vzdušným alergenùm v Evropě – projekt GA2LEN ................................................ 56
S. Bělohlávková
Standardizace provokaèních testù s potravinami
u pacientù s reakcemi okamžitého typu na potraviny ............................................... 57
V. Špičák
Standardy praktické alergenové imunoterapie ......................................................... 59
B. Novotná
Standard diagnostiky a péèe o pacienty s alergií na latex ....................................... 64
Z. Pelikán
Alergologie – QUO VADIS ? ................................................................................. 69
SLOVO ZÁVĚREM .............................................................................................. 71
CONTENTS
EDITORIAL .......................................................................................................... 1J. Blahoš
The active Society of Allergology and Clinical Immunology
of the Czech Medical Association Jan Evangelista Purkyně .................................. 7
C. John
Clinical Immunology still living ............................................................................... 7
P. Barták
How the time is going ................................................................................................ 9
1st PART
CSAKI – Czech Society of Allergology and Clinical Immunology ............................. 13
ALLERGOLOGY AND CLINICAL IMMUNOLOGY
Na Slupi and Charles Square .............................................................................. 22
Faculty Hospital Královské Vinohrady and 3th Medical
School Charles University Prague ........................................................................ 23
Paedidiatric allergology: Sokolská street – Motol – Bulovka .................................... 26
Brno .................................................................................................................. 28
Olomouc ............................................................................................................ 31
Hradec Králové ................................................................................................... 35
Ostrava .............................................................................................................. 37
Plzeň ................................................................................................................ 39
České Budějovice ................................................................................................ 40
Ústí nad Labem .................................................................................................. 41
50 years of the czech allergology and clinical immunology
– with smiling ...................................................................................................... 49
2nd PART
V. Špičák
Good practice in allergology with EBM .................................................................. 52
A revised nomenclature for allergy .......................................................................... 55
Standard SKIN PRICK TESTING and senzitisation to inhalant
allergens across Europe - a survey from the GA2LEN network ................................. 56
S. Bělohlávková
Standardization of food challenges in patients with immediate reactions
to foods - position paper from European Academy of Allergology
and Clinical Immunology ...................................................................................... 57
V. Špičák
Standards for practical allergen specific immunotherapy ........................................ 59
B. Novotná
Standard for diagnostics and treatment of the Latex Allergy ................................... 64
Z. Pelikán
Allergology – QUO VADIS? ................................................................................. 69
CONCLUSION .................................................................................................. 71
PŮVODNÍ PRÁCE
J. Libiger
Klasifikace v nesnázích ..................................................................................................... 116
R. Balon
Quo Vadis DSM? .............................................................................................................. 123
P. Grof
Jak diagnostikovat bipolární poruchu: problémy, které přinesly studie s potomky ........................................................................................................................... 127
M. Alda
Charakterizuje odpověď na profylaxi lithiem specifický typ bipolární
poruchy? ......................................................................................................................... 131
J. Volavka
Schizofrenie a násilí ......................................................................................................... 137
J. Horáček
Vliv polymorfizmu genu RGS4 (Regulator of G-protein signaling 4) na
regionální metabolizmus mozku (18FDG PET) a fenotypové proměnné
u schizofrenie ................................................................................................................... 141
CONTENTS
EDITORIAL ....................................................................................................................... 114J. Libiger
Troubles of Psychiatric Classification .................................................................................. 116
J. Balon
Quo Vadis DSM? ............................................................................................................... 123
P. Grof
Diagnosing bipolar disorders: recent challenges from the studies
of offspring ........................................................................................................................ 127
M. Alda
Does response to prophylactic lithium characterize a distinct form of bipolar
disorder? ........................................................................................................................... 131
J. Volavka
Schizophrenia and violence .................................................................................................. 137
J. Horáček
The influence of polymorphism for gene RGS4 (Regulator of G-protein
signaling 4) on regional brain metabolism (18FDG PET) and phenotypic
variables in schizophrenia .................................................................................................... 141
PROGRAM .......................................................................................................................... 4
Středa 10. června ................................................................................................................. 4
Čtvrtek 11. června .................................................................................................................. 4
Pátek 12. června ................................................................................................................... 5
Sobota 13. června ................................................................................................................. 6
Postery ................................................................................................................................ 7
KRÁTKÁ SDĚLENÍ .............................................................................................................. 10
POSTERY ........................................................................................................................... 70
CONTENTS
EDITORIAL ........................................................................................................................... 1
PROGRAMME ...................................................................................................................... 4
Wednesday 10th June ............................................................................................................ 4
Thursday 11th June ................................................................................................................ 4
Friday 12th June .................................................................................................................... 5
Saturday 13th June ............................................................................................................... 6
Posters ................................................................................................................................ 7
SHORT COMMUNICATIONS ................................................................................................. 10
POSTERS ........................................................................................................................... 70
EDITORIAL ........................................................................................................................ 1 PROGRAM ........................................................................................................................ 4
PLENÁRNÍ PŘEDNÁŠKY .................................................................................................. 12
ODBORNÁ SYMPOZIA
ANTIPSYCHOTIKA
Představují antipsychotika a halucinogeny opačné strany téže mince? .................................. 14
Faktory ovlivňující volbu a efekt antipsychotik ....................................................................... 15
ANTIDEPRESIVA
Farmakoterapie deprese napříč diagnostickým spektrem ...................................................... 16
PERSONALIZOVANÁ FARMAKOTERAPIE I.
Psychofarmakogenetika ..................................................................................................... 18
Kontroverzní témata v hodnocení účinnosti psychofarmak ..................................................... 19
TERAPIE V NEUROPSYCHIATRII I.
Neuropsychiatrický profil a farmakoterapie onemocnění z okruhu
atypických parkinsonských syndromù ................................................................................. 20
Organické psychotické poruchy a možnosti jejich léèby ........................................................ 21
FARMAKOTERAPIE V PEDOPSYCHIATRII
Psychofarmaka v dětství a dospívání .................................................................................... 22
Aktuální otázky z pedopsychiatrické praxe ........................................................................... 23
TERAPIE V NEUROPSYCHIATRII II.
Farmakologické a invazivní terapeutické metody v neuropsychiatrii ......................................... 23
Neuronální mechanizmy „Systému odměny" ........................................................................ 24
FARMAKOTERAPIE V GERONTOPSYCHIATRII
Neurobiologie a psychofarmaka ve stáří ............................................................................... 26
Úzkostné poruchy ve vyšším vìku a jejich léčba .................................................................... 27
PERSONALIZOVANÁ FARMAKOTERAPIE II.
Predikce odpovědi na psychofarmaka .................................................................................. 28
Proč naši pacienti nechtějí brát léky a co s tím můžeme dělat ............................................... 29
SNÍDANĚ ČNPS
Cirkadiánní rytmicita: od vědy po praktické použití ................................................................ 30
Indikace psychofarmak podle pohlaví ................................................................................... 31
NOVÝ VÝZKUM
Nový výzkum I.: Preklinické studie ....................................................................................... 32
Nový výzkum II.: Od animálních studií k pacientovi.................................................................. 34
Nový výzkum III.: Klinické studie .......................................................................................... 35
WORKSHOPY
1. Psychogenní poruchy hybnosti ......................................................................................... 38
2. Umíme diagnostikovat a léčit autismus? ............................................................................ 38
3. Sedmero hlavních hříchů: Hněv .......................................................................................... 38
4. Jaká farmaka neužívat jako stabilizátory nálady? ................................................................ 39
5. Disociativní křeče ............................................................................................................ 40
6. Diferenciální diagnostika a farmakoterapie demencí ............................................................. 40
7. Optimalizace terapie afektivních a psychotických poruch ..................................................... 41
8. Psychózy 3. druhu: adekvátní diagnostika a léčba akutních psychotických poruch ................. 41
SETKÁNÍ S ODBORNÍKEM
Prof. Jan Volavka, MD, PhD .................................................................................................. 42
Prof. MUDr. Daniela Ježová, DrSc. ......................................................................................... 42
VÝVĚSKOVÁ SDĚLENÍ
Preklinický výzkum I. (stres, úzkost a neuroprotektivita) .......................................................... 43
Klinický výzkum I. (afektivní a úzkostné poruchy) .................................................................... 47
Preklinický výzkum II. (návykové látky a antipsychotika) .......................................................... 49
Klinický výzkum II. (psychózy a závislosti) ............................................................................. 52
Preklinický výzkum III. (kognitiva) ........................................................................................... 55
Klinický výzkum III. (problémové oblasti farmakoterapie) ........................................................... 58
FIREMNÍ SYMPOZIA ............................................................................................................ 61
REJSTŘÍK AUTORÙ ............................................................................................................. 62
CONTENTS
EDITORIAL ........................................................................................................................... 1 PROGRAMME ...................................................................................................................... 4
PLENARY LECTURES ......................................................................................................... 12
SCIENTIFIC SYMPOSIA
ANTIPSYCHOTICS
Are antipsychotics and hallucinogens opposite sides of the same coin? .................................... 14
Factors influencing choice and effect of antipsychotics ............................................................ 15
ANTIDEPRESSANTS
Pharmacotherapy of depression in different psychiatric conditions ............................................. 16
PERSONALIZED PHARMACOTHERAPY I.
Psychopharmacogenetics ...................................................................................................... 18
Controversies in evaluation of drug efficacy .............................................................................. 19
THERAPY IN NEUROPSYCHIATRY I.
Neuropsychiatric profile and pharmacotherapy of the atypical parkinsonian syndromes .......................................................................................................................... 20
Organic psychoses and possibilities of pharmacological treatment ........................................... 21
PHARMACOTHERAPY IN CHILD PSYCHIATRY
Child and adolescent psychopharmacology ............................................................................ 22
Current issues in child and adolescent psychiatric care ........................................................... 23
THERAPY IN NEUROPSYCHIATRY II.
Pharmacological and invasive methods in neuropsychiatry ....................................................... 23
Neuronal mechanisms of the „Reward system" ....................................................................... 24
PHARMACOTHERAPY IN GERIATRIC PSYCHIATRY
Neurobiology and psychotropics in the elderly ........................................................................ 26
Anxiety disorders in the elderly and their treatment ................................................................. 27
PERSONALIZED PHARMACOTHERAPY II.
Prediction of treatment response to psychotropic drugs ........................................................... 28
Why our patients do not want to take drugs and what we can do with it .................................... 29
ČNPS BREAKFAST SYMPOSIA
Circadian rhythms: From science to clinical application .......................................................... 30
Indication of psychotropic drugs based on gender .................................................................. 31
FREE COMMUNICATIONS – NEW RESEARCH
New Research I.: Preclinical studies ..................................................................................... 32
New Research II.: From animal studies to patients ................................................................. 34
New Research III.: Clinical studies ........................................................................................ 35
WORKSHOPS
1. Psychogenic movement disorders ..................................................................................... 38
2. Are we able to diagnose and to treat autism? ..................................................................... 38
3. Seven deadly sins – Anger ................................................................................................ 38
4. Which drugs should not be used as mood stabilizers? ......................................................... 39
5. Dissociative seizures ........................................................................................................ 40
6. Differential diagnosis and pharmacotherapy of dementia ...................................................... 40
7. Optimalization of treatment of affective and psychotic disorders ............................................ 41
8. Psychoses of the third kind: Diagnostics and treatment of acute psychotic disorders ............. 41
MEET THE EXPERT
Prof. Jan Volavka, MD, PhD. ................................................................................................. 42
Prof. MUDr. Daniela Ježová, DrSc. ......................................................................................... 42
POSTER SESSIONS
Preclinical Research I. (Stress, anxiety and neuroprotectivity) .................................................. 43
Clinical Research I. (Affective and anxiety disorders) ............................................................... 47
Prelinical Research II. (Addictive substances and antipsychotics) ............................................. 49
Clinical Research II. (Psychotic disorders and addiction) .......................................................... 52
Prelinical Research III. (Cognitive drugs) ................................................................................. 55
Clinical Research III. (Problems in pharmocotherapy) ............................................................... 58
INDUSTRY-SPONSORED SATELLITE SYMPOSIA ................................................................. 61
AUTHOR INDEX ................................................................................................................... 62
EDITORIAL .......................................................................................................... 1
SVĚTOVÝ DEN ASTMATU 2007 – DNY ASTMATU A ALERGIE
F. Salajka
Česká iniciativa pro astma o. p. s. 2007 ................................................................... 7
Kutná Hora – Pohár horských kol ........................................................................... 8
Pískání pro zdraví ...................................................................................................... 9
SVĚTOVÝ DEN ASTMATU – PRAHA 4. 5. 2007
V. Špičák, J. Kratěnová
Astma a alergie ve střední a východní Evropě ........................................................ 11
P. Pohunek
Co přinášejí nové doporučené postupy GINA dětským astmatikům ................... 15
Vr. Sedlák
Těžké a obtížně léčitelné asthma bronchiale .......................................................... 19
E. Králíková
Závislost na tabáku – souvislosti, souèasná léèba a situace v ÈR ......................... 22
VI. SETKÁNÍ LÉKAŘŮ ČR A SR V LITOMYŠLI – 11.–12. 5. 2007
J. Krejsek
Přirozená imunita jako fundament zánětové reakce.
Kam až sahají její kořeny? ........................................................................................ 26
I. Stříž
Imunita respiraèního ústrojí ..................................................................................... 28
M. Hrubiško
Ľahká a ťažká astma – jedna choroba alebo rôzne entity? .................................... 33
J. Vokurka
Kortikoidy u rinosinusitid ......................................................................................... 37
B. Novotná
Probiotika v primární prevenci alergií – pøehled studií .......................................... 43
XII. ČESKOLIPSKÝ DEN ASTMATU A ALERGIE – 17. 5. 2007
P. Macháček
Alergie na plísně a jejich diagnostika ...................................................................... 46
H. Vávrová
Alergeny jedu blanokřídlého hmyzu ........................................................................ 50
SVĚTOVÝ DEN ASTMATU V OLOMOUCI
J. Bystroň ..................................................................................................................... 52
INFORMACE ................................................................................................................ 53
CONTENTS
EDITORIAL .................................................................................................................. 1
WORLD ASTHMA DAY 2007 – DAYS OF ASTHMA AND ALLERGY
F. Salajka
Czech Initiative for Asthma 2007 .................................................................................. 7
Kutná Hora – Championship of mountain bikes ............................................................. 8
Whistling for Health .................................................................................................... 9
WORLD ASTHMA DAY – PRAG 4. 5. 2007
V. Špičák, J. Kratěnová
Asthma and Allergy in the Central and Eastern Europe .............................................. 11
P. Pohunek
How do children with asthma profit from the new GINA guidelines .................................. 15
Vr. Sedlák
Difficult to control bronchial asthma ........................................................................... 19
E. Králíková
Tobacco depedence – the context, current treatment
and situation in th CR ............................................................................................... 22
VIth MEETING OF THE CZECH and SLOVAK PHYSICIANS,
LITOMYŠL – 11.–12. 5. 2007
J. Krejsek
Innate immunity as a fundament of inflammation.
Where does its roots reach? ...................................................................................... 26
I. Stříž
Respiratory System Immunity ...................................................................................... 28
M. Hrubiško
Mild and severe asthma – one disease or different entities? ............................................ 33
J. Vokurka
Corticosteroids at rhinosinusitis ................................................................................... 37
B. Novotná
Probiotics in primary prevention of allergic diseases –
summary of the studies ............................................................................................. 43
ČESKÁ LÍPA – XIIth DAY OF ASTHMA AND ALLERGY – 17. 5. 2007
P. Macháček
Allergy on fungi and their diagnotics ........................................................................... 46
H. Vávrová
Hymenoptera venom allergens .................................................................................... 50
WORLD ASTHMA DAY OLOMOUC
J. Bystroň ................................................................................................................... 52
INFORMATIONS ......................................................................................................... 53
OBSAH ................................................................................................................................ 5
1. PLENÁRNÍ PŘEDNÁŠKY ................................................................................................... 9
2. IMUNOPATOGENEZE INFEKČNÍCH CHOROB
Přednášky ..........................................................................................................................10
Postery ............................................................................................................................. 12
3. MEZIOBOROVÝ POHLED NA RINITIDY
Pøednášky .......................................................................................................................... 14
Postery .............................................................................................................................. 18
4. MEZIOBOROVÝ POHLED NA ASTMA
Pøednášky .......................................................................................................................... 19
Postery ............................................................................................................................... 22
5. PŘIROZENÁ IMUNITA
Přednášky ........................................................................................................................ 28
Postery ............................................................................................................................. 29
6. SLIZNIČNÍ IMUNITA, STŘEVNÍ MIKROFLÓRA, PROBIOTIKA
Přednášky ......................................................................................................................... 33
Postery ............................................................................................................................... 34
7. INFEKCE, NÁDORY, IMUNITA – CO PŘINESE NEJLEPŠÍ EFEKT?
Přednášky ......................................................................................................................... 40
Postery ............................................................................................................................... 42
8. TRANSPLANTAČNÍ IMUNOLOGIE
Přednášky ........................................................................................................................ 43
Postery ............................................................................................................................. 46
9. NOVINKY V LABORATORNÍ SEKCI I., II.
Přednášky ......................................................................................................................... 47
Postery .............................................................................................................................. 53
10. VÝVOJOVÁ IMUNOLOGIE
Přednášky ......................................................................................................................... 55
Postery .............................................................................................................................. 56
11. IMUNOTOXIKOLOGIE
Přednášky ......................................................................................................................... 57
Postery .............................................................................................................................. 60
12. PREVENCE A TERAPIE ALERGICKÝCH CHOROB
Přednášky ........................................................................................................................ 62
Postery ............................................................................................................................. 65
13. PROJEVY A LÉÈBA KOŽNÍCH IMUNOPATOLOGICKÝCH NEMOCÍ
Přednášky .......................................................................................................................... 66
Postery .............................................................................................................................. 68
14. IMUNOLOGIE A ALERGOLOGIE V PEDIATRII
Přednášky ............................................................................................................................ 70
Postery .............................................................................................................................. 71
15. ANAFYLAXE A JEJÍ SPOUŠTÌÈE
Přednášky ...........................................................................................................................72
Postery ............................................................................................................................... 74
16. NEUROIMUNOLOGIE
Postery .............................................................................................................................. 75
17. CHOROBY Z AUTOIMUNITY
Přednášky ...........................................................................................................................76
Postery .............................................................................................................................. 79
18. IMUNODEFICIENCE – NUTNOST VČASNÉ DIAGNOSTIKY
Přednášky .......................................................................................................................... 83
Postery ................................................................................................................................ 85
19. PROJEVY IMUNOPATOLOGICKY PODMÍNĚNÝCH STAVŮ V ÚSTNÍ DUTINĚ
Přednášky ...........................................................................................................................88
Postery .............................................................................................................................. 89
20. ZÁNĚT A IMUNITA
Přednášky ........................................................................................................................... 90
Postery ................................................................................................................................ 92
21. REPRODUKČNÍ IMUNOLOGIE
Přednášky ............................................................................................................................ 94
Postery ............................................................................................................................... 96
22. FUNKČNÍ GENOMIKA – APLIKACE V MEDICÍNÌ
Přednášky .............................................................................................................................. 98
Postery .................................................................................................................................. 99
23. SIGNALIZAÈNÍ MECHANISMY IMUNORECEPTORÙ
Přednášky .............................................................................................................................. 99
Postery ................................................................................................................................. 100
24. LABORATORNÍ IMUNOLOGIE
Přednášky .............................................................................................................................101
Postery ................................................................................................................................. 103
25. MODERNÍ OŠETŘOVATELSTVÍ V ALERGOLOGII A KLINICKÉ IMUNOLOGII
Přednášky .............................................................................................................................106
Postery ................................................................................................................................ 110
26. VÝŽIVA A IMUNITA
Přednášky ............................................................................................................................. 110
27. FIREMNÍ SYMPOZIUM MSD .............................................................................................. 111
28. ZÁVĚREČNÁ PŘEDNÁŠKA ............................................................................................... 111
JMENNÝ REJSTŘÍK ................................................................................................................ 112–117
Více...
ASTHMA, ALLERGY AND COPD 2006 – from the science to daily practice
GINA and the Patient
Suzanne S. Hurd ................................................................................................................ 6
Global Allergy and Asthma European Network (GA2LEN) and the Patient
P. Van Cauwenberge .......................................................................................................... 7
The patient Perspectives
Svein-Erik Myrseth ............................................................................................................ 8
How do we genuinely enhance doctor-patient partnership?
Martyn R Partridge............................................................................................................ 9
Primary Prevention of Allergy and Asthma
John Warner ....................................................................................................................... 10
Prevention of Allergy and Asthma – Dream or Reality?
Ulrich Wahn ....................................................................................................................... 11
From Asthma Mechanisms to Therapy in Practice
Peter Barnes ....................................................................................................................... 12
Asthma and COPD - one or two diseases?
Ronald Dahl ....................................................................................................................... 12
The burden of allergy: The patients' Voice
Erkka Valovirta .................................................................................................................. 13
Asthma, COPD and rhinitis in primary care
David Price ......................................................................................................................... 14
Pediatric asthma: How significant it is for the whole life?
Petr Pohunek ...................................................................................................................... 15
The Role of Genetics in the Evaluation of Asthma and its Treatment
Stephen T Holgate ............................................................................................................. 16
Allergy and asthma in future
Tari Haahtela ..................................................................................................................... 17
Message of nose to bronchi
Ester Seberová ................................................................................................................... 18
„Fighting for Breath" European patients' perspective on living
with severe asthma symptoms
Donna Covey ..................................................................................................................... 18
Refractory bronchial asthma – approach to our patients.
Vladimír Koblížek, Vratislav Sedlák, Zdeòka Paráková,
Bohuslav Král, František Salajka ..................................................................................... 19
Burden of chronic obstructive pulmonary disease (COPD) in Czech Republic
Jaromír Musil ..................................................................................................................... 19
European Pollen Information Service – benefit for patients
Siegfried Jaeger .................................................................................................................. 20
Smoking - cause or trigger
Viktor Kašák ...................................................................................................................... 21
Intervention in the indoor environment
Ariana Lajčíková ................................................................................................................ 21
We and Europe against food allergies
Simona Bìlohlávková ........................................................................................................ 22
CZECH INITIATIVE FOR ASTHMA ........................................................................... 23
ALLERGY AND ASTHMA IN THE CZECH REPUBLIC
Lékař a pacient. Partner a partner.
Physician and patient. Partner&Partner.
Viliam Meissner ................................................................................................................ 25
Kvalita života nemocných s tìžkým astmatem
Quality of life in patients with severe asthma
František Salajka .............................................................................................................. 29
Průduškové astma – od dětství do dospělosti
Bronchial asthma – From Childhood to Adulthood
Petr Pohunek ...................................................................................................................... 32
Poselství nosu průduškám
Message of nose to bronchi
Ester Seberová .................................................................................................................. 35
Pětileté sledování gravidních astmatiček
Asthma in Pregnancy- 5 years follow-up
Bronislava Novotná, Tomáš Pavlík ................................................................................. 39
Obtížně léčitelné astma (OLA) – pøístup k pacientovi s těžkým astmatem
Refractory bronchial asthma – approach to our patients
Vladimír Koblížek, Vratislav Sedlák, Zdeòka Paráková,
Bohuslav Král, František Salajka ................................................................................... 46
Aspirinem zlepšené astma (AZA) – vzácný fenotyp astmatu?
Aspirin-ameliorated asthma - a rare phenotype of asthma?
Krčmová Irena, Král Bohuslav, Paráková Zdena, Sedlák Vratislav,
Novotná Bronislava, Kašák Viktor, Halíková Jana, Chmelařová Soňa ........................ 49
Indukované sputum v èasné diagnostice astmatu
Induced sputum in early diagnostic of Asthma
Petr Panzner, Ivana Malkusová, Vladimír Hraško ......................................................... 52
Pohybová aktivita dìtských astmatikù
Physical activity in asthmatic children
Hana Janíčková, Zuzana Smrčková,
Jana Nosálová, Milena Dědičová .................................................................................... 55
Intervence ve vnitøním prostředí
Intervention in the Indoor Environment
Ariana Lajčíková ............................................................................................................... 59
Pylová informaèní služba
Pollen Information Service
Ondøej Rybníček ............................................................................................................... 63
Evropa a my proti potravinové alergii
We and Europe against Food Allergies
Simona Bělohlávková ....................................................................................................... 66
Farmakoekonomika astmatu v České republice
Pharmacoeconomics of asthma in Czech Republic
Viktor Kašák ..................................................................................................................... 67
Kukátko do historie ............................................................................ 6
Specifická alergenová imunoterapie – od empirie k důkazům ................. 9
Sublinguální alergenová imunoterapie ................................................. 10
Od „Pollatinu" k ORALAIRU .............................................................. 12
ORALAIR v „medicíně založené na důkazech" .................................... 14
ORALAIR v klinické praxi .................................................................. 20
Budoucnost alergenové imunoterapie .................................................. 23
Specific allergen immunotherapy – from empiricism to evidence ............ 9
Sub-lingual allergen immunotherapy .................................................. 10
From „Pollatin" to ORALAIR ............................................................. 12
ORALAIR in „Evidence based medicine" ............................................ 14
ORALAIR in clinical practice ............................................................. 20
Future of allergen immunotherapy ...................................................... 23